F. Coutrot et al.
The reaction mixture was then filtered through celite and concentrated
to give compound 4u (16 mg, quantitative) as a white foam.
24.0 ppm (C10); HRMS (ESI): calcd for C60H87F6N5O9P: 1166.6095
[MÀPF6]+, found: 1166.6146.
Uncomplexed form 4u: 1H NMR (600 MHz, 5.10À2 m in CD2Cl2, 298 K):
d=7.47 (s, 1H, H8), 7.45 (s, 1H, H20), 7.30 (s, 2H, H18), 6.92–6.87 (m, 4H,
HA HB), 6.87 (br t, 1H, HI), 6.83 (d, 2H, 4JHJÀHI =1.9 Hz, HJ), 6.74 (br t,
1H, H1), 4.33 (t, 2H, 3JH7ÀH6 =6.6 Hz, H7), 4.13–4.10 (m, 4H, HH), 4.10–
4.07 (m, 4H, HC), 3.79–3.73 (m, 8H, HD HG), 3.66 (s, 8H, HE HF), 3.37 (t,
2H, 3JH15–H14 =7.4 Hz, H15), 3.31 (q, 2H, 3JH2–H3 =3JH2–H1 =6.7 Hz, H2),
2.67 (t, 2H, 3JH10–H11 =7 Hz, H10), 1.94–1.84 (m, 2H, H6), 1.81–1.74 (m,
2H, H14), 1.65–1.59 (m, 2H, H11), 1.58–1.52 (m, 2H, H3), 1.44–1.37 (m,
2H, H13), 1.35–1.24 (m, 6H, H4 H5 H12), 1.29 ppm (s, 18H, H22);
13C NMR (150 MHz, 5.10À2 m in CD2Cl2, 298 K): d=168.6(CK), 160.9,
[1]rotaxane 6: A solution of the [1]rotaxane 5 (52 mg, 0.040 mmol,
1 equiv) in CH2Cl2 (10 mL) was washed with an aqueous solution of
NaOH 1m (2ꢃ5 mL). After extraction of the aqueous layer with CH2Cl2
(10 mL), the combined organic layers were dried over MgSO4 and evapo-
rated to obtain the deprotonated [1]rotaxane 6 (43 mg, 94%) as a white
foam. Rf 0.50 (CH2Cl2/Acetone 70:30); 1H NMR (600 MHz, 5.10À3 m in
CD2Cl2, 298 K): d=8.09 (s, 1H, H8), 7.49–7.39 (m, 3H, H29 H30), 7.07–
7.02 (m, 2H, H28), 6.85–6.79 and 6.72–6.67 (2 m, 4H, HA HB), 6.75 (s, 1H,
H20), 6.66 (s, 2H, HJ), 6.56 (s, 1H, HI), 6.50 (s, 2H, H18), 6.37 (br t, 1H,
3
H1), 5.28 (s, 2H, H26), 4.22 (t, 2H, JH7–H6 =6 Hz, H7), 4.25–4.10 and 3.95–
3.87 and 3.87–3.81 (3 m, 8H, HH HC), 4.09–4.04 and 3.94–3.88 and 3.70–
3.63 (3 m, 8H, HD HG), 3.76–3.69 and 3.69–3.63 and 3.61–3.56 (3 m, 8H,
HE HF), 3.43–3.37 (m, 2H, H2), 3.22 (t, 2H, 3JH15ÀH14 =6.9 Hz, H15), 2.59
(t, 2H, 3JH10ÀH11 =7.9 Hz, H10), 1.91–1.85 (m, 2H, H6), 1.80–1.72 (m, 4H,
H11 H14), 1.66–1.59 (m, 2H, H3), 1.60–1.55 (m, 4H, H12 H13), 1.39–1.32
(m, 2H, H4), 1.29 (s, 18H, H22), 1.25–1.19 ppm (m, 2H, H5); 13C NMR
(150 MHz, 5.10À2 m in CD2Cl2, 298 K): d=166.6 (CK), 160.8, 160.4, 148.8,
149.1 and 137.0 (CIV
BMP25C8), 154.2 (C19), 147.5 (C17), 129.5 or 128.7
arom
(C9), 123.0 (C20), 122.5 (C8), 122.3 and 115.2 (CA CB), 116.4 (C18), 107.2
(CJ), 106.5 (CI), 71.1 and 71.0 (CE CF), 70.5 and 69.9 (CD CG), 69.1 and
68.9 (CC CH), 53.2 (C15), 50.9 (C7), 40.6 (C2), 35.6 (C21), 31.5 (C22), 30.3
(C6), 29.5 (C3), 29.3 (C11), 28.2 (C12), 26.6 (C14), 26.7 and 26.3 (C4 C5),
26.1 (C13), 25.1 ppm (C10).
Pseudo[1]rotaxane 4: 1H NMR (600 MHz, 5.10À2 m in CD2Cl2, 298 K):
d=8.65 (br s, 2H, H16), 7.53 (s, 1H, H20), 7.52 (s, 1H, H8), 7.42 (s, 2H,
and 137.4 (CIVÀarom BMP25C8), 152.2 (C19), 149.6 and 149.0 (CIVÀarom
BMP25C8
and C17), 146.6 (C9), 132.4 (C27), 129.8 and 129.7 (C29 C30), 129.0 (C8),
128.7 (C28), 122.2, 122.1, and 114.1 (CA CB), 112.0 (C20), 107.9 (C18), 107.6
(CI), 104.8 (CJ), 71.7, 71.5, 71.4, 71.3, and 71.2 (CE CF), 70.5, 70.4, and
70.0 (CD CG), 69.5, 68.9, and 68.6 (CC, CH), 54.8 (C7), 54.0 (C26), 44.6
(C15), 40.5 (C2), 35.3 (C21), 31.8 (C22), 30.3 (C14), 30.1, 28.0, and 27.9 (C6
C12 C13), 28.1 (C3), 27.1 (C4), 26.7 (C5), 26.3 (C11), 23.5 (C10); HRMS
(ESI): m/z calcd for C60H87F6N5O9P: 1166.6156 [M+H]+; found:
1166.6146.
4
H18), 6.97–6.93 and 6.90–6.86 (2 m, 4H, HA HB), 6.94 (d, 2H, JHJ–HI
=
2 Hz, HJ), 6.68 (br t, 1H, H1), 6.20 (br t, 1H, HI), 4.37–4.34 (m, 2H, H7),
4.42–4.14 and 4.06–4.02 (2 m, 8H, HH HC), 3.98–3.93, 3.85–3.81, and 3.79–
3.63 (3 m, 8H, HD HG), 3.79–3.63 and 3.60–3.49 (2 m, 8H, HE HF), 3.60–
3.54 (m, 2H, H15), 3.19 (q, 2H, 3JH2–H3 =3JH2–H1 =6.4 Hz, H2), 2.43 (t, 2H,
3JH10–H11 =8 Hz, H10), 1.94–1.87 (m, 2H, H6), 1.63–1.56 (m, 2H, H14), 1.43–
1.37 (m, 2H, H3), 1.35–1.24 (m, 4H, H5 H11), 1.29 (s, 18H, H22), 1.13–1.07
(m, 2H, H4), 1.07–1.01 (m, 2H, H12), 0.91–0.84 ppm (m, 2H, H13);
13C NMR (150 MHz, 5.10À2 m in CD2Cl2, 298 K): d=167.3(CK), 160.1,
148.2, 137.8, and 137.2 (CIV arom BMP25C8), 154.2 (C19), 135.6 (C17), 129.5 or
128.7 (C9), 124.9 (C20), 122.8 and 113.2 (CA CB), 122.3 (C8), 117.3 (C18),
107.6 (CI), 106.4 (CJ), 72.1 and 71.3 (CE CF), 70.8 (CD CG), 69.0 and 68.7
(CC CH), 52.3 (C15), 50.9 (C7), 39.9 (C2), 35.7 (C21), 31.6 (C22), 29.9 and
29.1 (C3 C11), 29.4 (C12), 28.8 (C6), 27.7 (C14), 26.2 (C13), 25.8 (C5), 25.6
(C10), 25.4 ppm (C4).
Acknowledgements
We thank the Ligue Nationale Contre le Cancer for PhD financial sup-
port.
[1]Rotaxane 5: A solution of compound 4 (300 mg, 0.28 mmol, 1 equiv)
dissolved in CH2Cl2 (10 mL) was added dropwise over 24 h to a solution
of benzyl bromide (139 mL) and CH2Cl2 (418 mL). The mixture was stir-
red for further 72 h at RT. CH2Cl2 was then evaporated and the excess of
benzyl bromide was removed by filtration on a silica gel column (solvent
gradient elution CH2Cl2 to CH2Cl2/MeOH 95:5). The remaining solid
(290 mg) was then diluted in CH2Cl2 (20 mL). To this solution was added
NH4PF6 (189 mg, 1.16 mmol, 5 equiv) and H2O milliQ (10 mL): the bi-
phasic solution was stirred vigorously for 30 min. The aqueous layer was
extracted with CH2Cl2 (3ꢃ20 mL) and the combined organic layers were
dried over MgSO4 and concentrated under vacuum. The crude was puri-
fied successively by chromatography on a silica gel column (CH2Cl2/
MeOH 99:1) and LH20 sephadex column (CH2Cl2/MeOH 50:50) to give
[1]rotaxane 5 (96 mg, 27%) and deprotonated thread 6u (123 mg, 38%)
as white foams. Rf 0.52 (CH2Cl2/Acetone 70/30); 1H NMR (600 MHz,
5.10À3 m in CD2Cl2, 298 K): d=8.64 (br s, 2H, H16), 8.47 (s, 1H, H8), 7.52
(s, 1H, H20), 7.47–7.43 (m, 3H, H29 H30), 7.42 (s, 2H, H18), 7.35–7.30 (m,
2H, H28), 6.97–6.92 and 6.90–6.85 (2 m, 4H, HA HB), 6.87 (s, 2H, HJ),
[1] For some recent examples, see: a) V. Blanco, A. Carlone, K. D.
51, 5166–5169; b) A. Fernandes, A. Viterisi, F. Coutrot, S. Potok,
Frasconi, M. A. Giesener, Z. Zhu, Z. Liu, K. J. Hartlieb, R. Carmie-
[2] For some recent examples, see: a) C. Wang, D. Cao, A. C. Fahren-
bach, L. Fang, M. A. Olson, D. C. Friedman, S. Basu, S. K. Dey,
b) S. M. Goldup, D. A. Leigh, T. Long, P. R. McGonigal, M. D.
5573; d) Z. Zhu, A. C. Fahrenbach, H. Li, J. C. Barnes, Z. Liu, S. M.
Dyar, H. Zhang, J. Lei, R. Carmieli, A. A. Sarjeant, C. L. Stern,
11709–11720; e) A. C. Fahrenbach, K. J. Hartlieb, C.-H. Sue, C. J.
Bruns, G. Barin, S. Basu, M. A. Olson, Y. Y. Botros, A. Bagabas,
[3] a) Y. Ferrand, Q. Gan, B. Kauffmann, H. Jiang, I. Huc, Angew.
7575; b) Q. Gan, Y. Ferrand, C. Bao, B. Kauffmann, A. Grꢀlard, H.
3
6.43 (br t, 1H, H1), 6.15 (s, 1H, HI), 5.70 (s, 2H, H26), 4.60 (t, 2H, JH7–
H6 =5.6 Hz, H7), 4.25–4.14 and 4.08–4.02 (2 m, 8H, HH HC), 3.99–3.93 and
3.86–3.77 and 3.77–3.69 (3 m, 8H, HD HG), 3.77–3.69 and 3.63–3.55 and
3.55–3.49 (3 m, 8H, HE HF), 3.55–3.49 (m, 2H, H15), 3.27–3.20 (m, 2H,
H2), 2.58 (t, 2H, 3JH10–H11 =8 Hz, H10), 2.18–2.20 (m, 2H, H6), 1.62–1.54
(m, 2H, H14), 1.57–1.50 (m, 2H, H3), 1.46–1.39 (m, 2H, H11), 1.40–1.33
(m, 2H, H5), 1.34–1.29 (m, 2H, H4), 1.29 (s, 18H, H22), 1.12–1.04 (m, 2H,
H12), 0.91–0.82 ppm (m, 2H, H13); 13C NMR (150 MHz, 5.10À2
m in
CD2Cl2, 298 K): d=167.9 (CK), 160.8, 160.1, 149.5, 147.5, and 138.6
(CIVÀarom BMP25C8), 154.2 (C19), 145.8 (C9), 135.6 (C17), 131.8 (C27), 130.1 and
130.0 (C29 C30), 128.9 (C28), 128.8 (C8), 124.9 (C20), 122.7, 122.1, 115.4, and
113.2 (CA CB), 117.3 (C18), 107.5 (CI), 106.2 (CJ), 72.2, 71.4, and 71.3 (CE
CF), 70.8, 70.7, 70.4, and 70.2 (CD CG), 69.3, 68.9, and 68.6 (CC, CH), 55.4
(C26), 54.8 (C7), 52.4 (C15), 39.3 (C2), 35.7 (C21), 31.6 (C22), 29.1 (C12), 28.8
(C3), 28.0 (C6), 27.6 (C14), 27.0 (C11), 26.3 (C13), 25.0 (C4), 24.6 (C5),
75, 6516–6531; c) S. Bonnet, J. P. Collin, M. Koizumi, P. Mobian,
2988
ꢂ 2013 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
Chem. Eur. J. 2013, 19, 2982 – 2989